ACR 2005 Media Kit
Media Alert
Pivotal study confirms promise for MabThera® (rituximab) in rheumatoid arthritis
Press Release
MabThera – a unique approach providing lasting benefits for patients with rheumatoid arthritis
Comprehensive long-term clinical success achieved in difficult-to-treat patients following just two administrations, two weeks apart
Backgrounders
Innovating the management of rheumatoid arthritis (RA)
Understanding the role of B cells
Promising future ahead for Roche in rheumatoid arthritis
Rituximab in rheumatoid arthritis
- © 2009 F. Hoffmann-La Roche Ltd. The site is intended for non US physicians and scientific media only.Prescribing information, pricing and indications for MabThera may differ from country to country.Please consult your local Roche company for such information you may be interested in.